(MENAFN- GlobeNewsWire - Nasdaq) Opportunities span precision therapeutics, personalized medicine, respiratory diagnostics and proteomics, driven by AI-enabled biosensors, rapid screening and antibody alternatives.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Aptamers Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The global aptamers market is experiencing rapid growth as biotechnology and pharmaceutical organizations increase their investment in targeted therapeutics, molecular diagnostics, and advanced biomarker research. The market is projected to grow from $3.25 billion in 2025 to $4.05 billion in 2026, representing a compound annual growth rate (CAGR) of 24.6%. Historical growth has been supported by rising demand for precision therapeutics, advances in molecular biology techniques, greater research funding for aptamer technologies, the increasing prevalence of chronic diseases, and the expansion of biotechnology research infrastructure.
Strong momentum is expected to continue through the end of the decade. The aptamers market is forecast to reach $9.84 billion by 2030, expanding at a CAGR of 24.8%. Key market growth drivers include the increasing adoption of aptamer-based diagnostics, integration with artificial intelligence and biosensing platforms, continued development of personalized medicine, and rising collaboration between pharmaceutical and biotechnology companies. Expanding healthcare and research capabilities in emerging markets are also expected to create new opportunities for aptamer technology providers.
Major aptamers market trends include the development of advanced targeted drugs, increased use of high-throughput screening, customizable aptamer design, and integration with biosensors and diagnostic systems. Aptamers are also gaining attention across therapeutic development, research, diagnostics, biomarker detection, and drug delivery applications. Their ability to support highly selective molecular targeting is strengthening their position in next-generation life sciences research and clinical innovation.
The rising prevalence of chronic respiratory diseases is contributing to aptamers market growth. Aptamer-based technologies can support the detection of respiratory syncytial virus, facilitate earlier disease identification, and enable treatment-related research. According to the Australian Institute of Health and Welfare, chronic obstructive pulmonary disease accounted for 3.6% of Australia's total disease burden and 50% of the disease burden associated with respiratory conditions in 2023. The need for more accurate diagnostic and monitoring technologies is expected to increase demand for aptamer-based platforms in respiratory healthcare.
Product innovation is another important factor shaping the global aptamers industry. In March 2023, UK-based Aptamer Group PLC launched Optimer-Fc for automated immunohistochemistry applications. The reagent is designed to integrate Optimer binders into established workflows and improve the accuracy and selectivity of disease biomarker detection. Aptamer Group has worked with immunohistochemistry businesses to validate the reagent's performance while engaging with pharmaceutical companies on potential trials. The technology also provides a new patentable option as patents covering established immunohistochemistry antibodies expire.
Strategic acquisitions are expanding the role of aptamer-based proteomics within multi-omics research. In June 2025, Illumina acquired SomaLogic for $350 million in cash, with up to an additional $75 million tied to performance-based milestones. The acquisition supports Illumina's multi-omics strategy by adding SomaLogic's SomaScan aptamer-based proteomics platform. This technology is designed for high-throughput protein measurement and biomarker discovery, enabling researchers to analyze thousands of proteins from biological samples. The transaction highlights growing commercial interest in combining genomics, proteomics, and aptamer technologies.
North America was the largest region in the aptamers market in 2025. The geographic regions covered by the market include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Type: DNA Aptamers; XNA Aptamers; RNA Aptamers
2) By Technology: SELEX; X Aptamer; Maras Technique
3) By Application: Therapeutics Development; Research and Development; Diagnostic; Other Applications
Subsegments:
1) By DNA Aptamers: Single-Stranded DNA (ssDNA) Aptamers; Double-Stranded DNA (dsDNA) Aptamers
2) By XNA Aptamers: Peptide Nucleic Acid (PNA) Aptamers; Locked Nucleic Acid (LNA) Aptamers; Glycyl Nucleic Acid (GNA) Aptamers
3) By RNA Aptamers: Small Interfering RNA (siRNA) Aptamers; Short Hairpin RNA (shRNA) Aptamers; Long Non-Coding RNA (lncRNA) Aptamers
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment